Dose Insider / Glossary / SYNERGY-NASH

SYNERGY-NASHThe liver trial of tirzepatide

Updated November 20, 2026 路 3 min read 路 Loomba et al., N Engl J Med 2024; WEGOVY label

SYNERGY-NASH is a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis, or MASH, the inflammatory form of fatty liver disease formerly called NASH. It enrolled 190 adults whose liver biopsies showed MASH with moderate or severe scarring, stage F2 or F3, and gave them tirzepatide 5, 10 or 15 mg or placebo once a week for 52 weeks.

62%Tirzepatide 15 mg, resolution of MASH by week 52
Resolution of MASH by week 52Without worse scarring, % of patientsTirzepatide 15 mg62%Tirzepatide 10 mg56%Tirzepatide 5 mg44%Placebo10%Resolution of MASH by week52Without worse scarring, % of patientsTirzepatide 15 mg62%Tirzepatide 10 mg56%Tirzepatide 5 mg44%Placebo10%

Judged by liver biopsy at the start and at week 52.

On this page

MASH resolved without worse scarring in 44% to 62% on tirzepatide, against 10% on placebo. It was published in the New England Journal of Medicine in 2024.1

How the trial was run

The trial was a multicenter, double-blind, placebo-controlled dose-finding study. Everyone had a liver biopsy at the start to confirm MASH and the fibrosis stage, and another at week 52 to judge the effect of treatment. The main outcome was resolution of MASH without worsening of fibrosis. A main secondary outcome was an improvement of at least one fibrosis stage without worsening of MASH.1

Of the 190 people randomized, 157 had a week-52 biopsy that could be evaluated. For those without one, the analysis assumed they would follow the pattern of the placebo group, a cautious choice.1

What it found

Loomba et al., 2024.1

How to read the result

The trial measured two different things. MASH resolution concerns inflammation and injury of liver cells; fibrosis is scarring. The Wegovy label spells out the standard definition used in these trials: resolution means a score of 0 to 1 for inflammation in the liver lobules and 0 for ballooning of liver cells, with any amount of fat.2 Tirzepatide's effect on resolution was large and grew with the dose. Its effect on scarring was smaller, about 21 to 25 percentage points over placebo, and did not grow with the dose.1

Where it fits

Semaglutide already has a label for this condition. The Wegovy injection is approved for noncirrhotic MASH with moderate to advanced fibrosis, stages F2 to F3, under accelerated approval based on improvement in MASH and fibrosis, which may depend on confirmation in further trials.2 In its 72-week trial of 800 people with F2 or F3 fibrosis, MASH resolved without worse scarring in 63% on semaglutide 2.4 mg against 34% on placebo, and scarring improved without worse MASH in 37% against 22%. Two pathologists read each biopsy, with a third settling disagreements.2 The trials differ in length and design, so the numbers are not directly comparable with SYNERGY-NASH. Tirzepatide has no such use on the Zepbound or Mounjaro labels in the versions we read.3 Other drugs tested for the same condition include pemvidutide and survodutide, which pair GLP-1 with the glucagon receptor. In a 24-week phase 2b trial, MASH resolved in 58% on pemvidutide 1.2 mg and 52% on 1.8 mg against 20% on placebo, while the gain in fibrosis was not statistically clear.4,5

Limits

The trial was phase 2, with about 40 to 50 people per group, and lasted one year; it was designed to choose doses and estimate effects, not to change practice on its own. It was funded by Eli Lilly, the maker of tirzepatide, and is registered as NCT04166773.1 Our page on nausea on a GLP-1 covers the most common side effect.

Sources

  1. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. Funded by Eli Lilly; NCT04166773. doi:10.1056/NEJMoa2401943
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov
  3. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 1; and MOUNJARO prescribing information, NDA 215866/S-052, revised April 2026, section 1. accessdata.fda.gov
  4. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for MASH (IMPACT): 24-week results from a phase 2b study. Lancet 2025;406:2644-2655. doi:10.1016/S0140-6736(25)02114-2
  5. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD. Nat Med 2026;32:2948-2958. doi:10.1038/s41591-026-04479-3

Related analyses

Log your doses with liver test results and see them over time.

Open Dose Insider